Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2007 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2017 1
2018 3
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen.
Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, Hayes C, Rowley C, Dias J, Harper S, Barnbrook K, Hock M, Coles C, Yang W, Aleksic M, Lin AB, Robinson R, Dukes JD, Liddy N, Van der Kamp M, Plowman GD, Vuidepot A, Cole DK, Whale AD, Chillakuri C. Poole A, et al. Among authors: haidar jn. Nat Commun. 2022 Sep 10;13(1):5333. doi: 10.1038/s41467-022-32811-1. Nat Commun. 2022. PMID: 36088370 Free PMC article.
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H, Li Y, Malabunga M, Carpenito C, Eastman SW, Shen Y, Wang G, Inigo I, Surguladze D, Pennello AL, Persaud K, Hindi S, Topper M, Chen X, Zhang Y, Bulaon DK, Bailey T, Lao Y, Han B, Torgerson S, Chin D, Sonyi A, Haidar JN, Novosiadly RD, Moxham CM, Plowman GD, Ludwig DL, Kalos M. Kotanides H, et al. Among authors: haidar jn. Cancer Immunol Res. 2020 Oct;8(10):1300-1310. doi: 10.1158/2326-6066.CIR-20-0304. Epub 2020 Jul 27. Cancer Immunol Res. 2020. PMID: 32873605
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: haidar jn. J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. J Immunother Cancer. 2018. PMID: 29712568 Free PMC article.
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: haidar jn. J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6. J Immunother Cancer. 2018. PMID: 29866166 Free PMC article.
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H, Sattler RM, Lebron MB, Carpenito C, Shen J, Li J, Surguladze D, Haidar JN, Burns C, Shen L, Inigo I, Pennello AL, Forest A, Chen X, Chin D, Sonyi A, Topper M, Boucher L, Sharma P, Zhang Y, Burtrum D, Novosiadly RD, Ludwig DL, Plowman GD, Kalos M. Kotanides H, et al. Among authors: haidar jn. Mol Cancer Ther. 2020 Apr;19(4):988-998. doi: 10.1158/1535-7163.MCT-19-0893. Mol Cancer Ther. 2020. PMID: 32241872
Backbone flexibility of CDR3 and immune recognition of antigens.
Haidar JN, Zhu W, Lypowy J, Pierce BG, Bari A, Persaud K, Luna X, Snavely M, Ludwig D, Weng Z. Haidar JN, et al. J Mol Biol. 2014 Apr 3;426(7):1583-99. doi: 10.1016/j.jmb.2013.12.024. Epub 2013 Dec 28. J Mol Biol. 2014. PMID: 24380763
14 results